Symbolbild · KI-generiert
Clinuvel Pharmaceuticals (Australia)
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.
Company profile
Clinuvel Pharmaceuticals is an Australian biopharmaceutical company specialising in the development of therapies for rare genetic disorders of the skin and nervous system. Its lead product Scenesse (afamelanotide) is approved in Europe and the United States for the treatment of erythropoietic protoporphyria.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Clinuvel Pharmaceuticals (Australia) | CUV | ASX | 311 Mio. USD |
| Sanara MedTech Inc. | SMTI | NASDAQ | 310 Mio. USD |
| Vitalhub Corp. | VHI | TSX | 309 Mio. USD |
| Vanda Pharmaceuticals Inc. | VNDA | NASDAQ | 307 Mio. USD |
| Opus Genetics, Inc. | IRD | NASDAQ | 306 Mio. USD |
| Scribe Therapeutics Inc. | SCTX | NASDAQ | 315 Mio. USD |
| Organogenesis Holdings Inc. | ORGO | NASDAQ | 305 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.